Jeffrey Nathan Sharpe - 22 May 2026 Form 4 Insider Report for Conexeu Sciences Inc. (CNXU)

Reporting relationship: Director
Issuer ticker: CNXU
Reported as of: 22 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2026, 06:16:20 UTC
Prior SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeff Sharpe

Key filing fact

Jeffrey Nathan Sharpe filed Form 4 for Conexeu Sciences Inc. (CNXU) on 26 May 2026.

Key facts

This page summarizes Jeffrey Nathan Sharpe's Form 4 filing for Conexeu Sciences Inc. (CNXU).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 May 2026, 06:16.

Change

Previous filing in this sequence was filed on 11 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127816 Primary reporting owner

Sharpe Jeffrey Nathan

Relationship: Director
Address: 50 WEST LIBERTY STREET, SUITE 880, RENO
Signature: /s/ Jeff Sharpe
Signature date: 26 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNXU transaction

Common Stock

Options Exercise

Transaction value
Shares: +500,000
Change %: +100%
Price: $0.001000^*
Shares after: 1,000,000
Date: 22 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNXU transaction Derivative

Performance Warrants

Options Exercise

Transaction value
Shares: -500,000
Change %: -33%
Price: $0.000000^*
Shares after: 1,000,000
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.001000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

Footnote F2

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. The Performance Warrants will vest and be exercisable upon the following milestone events: (i) 500,000 Performance Warrants upon the Issuer's shares of common stock being listed on a recognized stock exchange in North America, which have vested; (ii) 500,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (iii) 500,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.